Released Nov 6, 2014, after the close
10-Q filed Nov 7, 2014, 38 days after period end · 0001019687-14-004114
Q3 2014 · 10-Q
Revenue$6.01M$6.01M +8.7% vs Q3 2013−12.6% vs Q2 2014
Net Income-$1.32M-$1.32M N/M vs Q3 2013N/M vs Q2 2014
EPS Diluted-$0.01-$0.01 — vs Q3 2013N/M vs Q2 2014
Operating Income-$1,275,000N/M
Operating Cash Flowderived-$1,446,000N/M
Free Cash Flowderived-$1,580,000N/M
Margins · derived
Operating margin-21.2%−17.0 pt vs Q3 2013
Net margin-21.9%−17.7 pt vs Q3 2013
What the release said
The release
Same quarter
| Metric | Q3 2014 | Q3 2013 | Q3 2012 | Q3 2011 |
|---|---|---|---|---|
| Revenue | $6.01M | $5.53M | $6.05M | $5.87M |
| Net Income | -$1.32M | -$234.00K | $54.00K | -$837.00K |
| EPS Diluted | -$0.01 | $0.00 | $0.00 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR